5-(4,4,5,5-四甲基-1,3,2-二氧硼烷)-1-[[2-(三甲基甲硅烷基)乙氧基]甲基]-1H-吡唑 | 903550-12-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硼酸衍生物
• 中文名称: 5-(4,4,5,5-四甲基-1,3,2-二氧硼烷)-1-[[2-(三甲基甲硅烷基)乙氧基]甲基]-1H-吡唑
• 英文名称: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole
• 英文别名: 5-(4,4,5,5-tetramethyl-[1,3 ,2]dioxaborolan-2-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrazole；trimethyl-[2-[[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]methoxy]ethyl]silane
• CAS: 903550-12-9
• 化学式: C₁₅H₂₉BN₂O₃Si
• mdl: MFCD09037502
• 分子量: 324.303
• InChiKey: FVCZMGOMGHMAIX-UHFFFAOYSA-N

物化性质

• 沸点：
  395.1±27.0 °C(Predicted)
• 密度：
  1.01±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.16
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  45.5
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(2-Trimethylsilylethoxy)methylpyrazole-5-boronic acid, pinacol ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(2-Trimethylsilylethoxy)methylpyrazole-5-boronic acid, pinacol ester
CAS number: 903550-12-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C15H29BN2O3Si
Molecular weight: 324.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(4,4,5,5-四甲基-1,3,2-二氧硼烷)-1-[[2-(三甲基甲硅烷基)乙氧基]甲基]-1H-吡唑 在 copper(l) iodide 、 四(三苯基膦)钯 、 N,N-二甲基甘氨酸 、 sodium carbonate 、 caesium carbonate 作用下， 以 乙二醇二甲醚 、 水 、 二甲基亚砜 为溶剂， 反应 16.5h， 生成 tert-butyl N-[[6-[4-[2-(2-trimethylsilylethoxymethyl)pyrazol-3-yl]phenoxy]-3,4-dihydro-2H-chromen-2-yl]methyl]carbamate
  参考文献：
  名称：

  [EN] PYRAZOLE DERIVATIVES WHICH INHIBIT LEUKOTRIENE PRODUCTION
  [FR] DÉRIVÉS DE PYRAZOLE INHIBANT LA PRODUCTION DE LEUCOTRIÈNE

  摘要：

  本发明涉及以下式（I）的化合物或其药学上可接受的盐，其中A1、A2、L1和B如本文所定义。式（I）的化合物可用作白三烯A4水解酶（LTA4H）的抑制剂，并用于治疗与LTA4H相关的疾病。本发明还涉及包含式（I）的化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，以及制备这些化合物的方法。

  公开号：

  WO2014014874A1
• 作为产物：
  描述：

  2-(三甲基硅烷基)乙氧甲基氯 在 正丁基锂 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 生成 5-(4,4,5,5-四甲基-1,3,2-二氧硼烷)-1-[[2-(三甲基甲硅烷基)乙氧基]甲基]-1H-吡唑
  参考文献：
  名称：

  Efficient and simple synthesis of 3-aryl-1H-pyrazoles

  摘要：

  Efficient preparation of 3-aryl-1H-pyrazoles by reaction of 1-protected-5-(4,4.5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)1H-pyrazoles with (het)aryl halides is described. The choice of THP protecting. group is discussed. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2006.04.125
• 作为试剂：
  描述：

  5-(4,4,5,5-四甲基-1,3,2-二氧硼烷)-1-[[2-(三甲基甲硅烷基)乙氧基]甲基]-1H-吡唑 、 5-bromo-N-[4-[chloro(difluoro)methoxy]phenyl]-6-(3-hydroxypyrrolidin-1-yl)pyridine-3-carboxamide 在 5-(4,4,5,5-四甲基-1,3,2-二氧硼烷)-1-[[2-(三甲基甲硅烷基)乙氧基]甲基]-1H-吡唑 作用下， 生成 (R)-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)nicotinamide
  参考文献：
  名称：

  US20140343086A1

  摘要：

  公开号：

文献信息

• [EN] 5-MORPHOLIN-4-YL-PYRAZOLO[4,3-B]PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 5-MORPHOLIN-4-YL-PYRAZOLO[4,3-B]PYRIDINE
  申请人：MERCK PATENT GMBH

  公开号：WO2020049017A1

  公开（公告）日：2020-03-12

  Compounds of the formula Ia and Ib in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of ATR, and can be employed for the treatment of diseases such as cancer.

  公式Ia和Ib中的化合物，其中R1、R2和R3的含义如权利要求1所述，是ATR的抑制剂，并且可用于治疗诸如癌症之类的疾病。
• HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150191464A1

  公开（公告）日：2015-07-09

  Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with R a and R b ; and R 1 and R 2 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.

  公开的是Formula (I)的化合物或其盐，其中：HET是从吡唑基、吲哚基、吡咯并[2,3-b]吡啶基、吡咯并[2,3-d]嘧啶基、吡唑并[3,4-b]吡啶基、吡唑并[3,4-d]嘧啶基、2,3-二氢-1H-吡咯并[2,3-b]吡啶基、咪唑并[4,5-b]吡啶基和嘌呤基中选择的杂环芳基，其中所述杂环芳基被R a 和R b 取代；以及R 1 和R 2 在此处定义。还公开了使用这些化合物作为IRAK4调节剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓炎症性和自身免疫性疾病方面是有用的。
• [EN] AKT / PKB INHIBITORS<br/>[FR] INHIBITEURS D'AKT/PKB
  申请人：ALMAC DISCOVERY LTD

  公开号：WO2011055115A1

  公开（公告）日：2011-05-12

  The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.

  这项发明涉及一系列具有特定活性的化合物，作为丝氨酸-苏氨酸激酶AKT的抑制剂。还提供了包含这些化合物的药物组合物，以及治疗癌症的方法。
• COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1
  申请人：DODD Stephanie Kay

  公开号：US20130310395A1

  公开（公告）日：2013-11-21

  The present invention relates to compounds of formula (I): in which Y, Y 1 , R 1 , R 2 , R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

  本发明涉及式(I)的化合物：其中Y、Y1、R1、R2、R3和R4如发明摘要中所定义；能够抑制BCR-ABL1及其突变体的活性。本发明还提供了一种制备本发明化合物的方法，包括这种化合物的制药制剂以及使用这种化合物治疗癌症的方法。
• NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF
  申请人：Nakamura Masayuki

  公开号：US20140005185A1

  公开（公告）日：2014-01-02

  The present invention provides an imidazooxazine compound represented by Formula (I) or a salt thereof, wherein A, B, C, and D are as defined in the specification.

  本发明提供了一种由化学式(I)表示的咪唑氧嗪化合物或其盐，其中A、B、C和D如规范中所定义。